CLINICAL RESEARCH: INTERVENTIONAL CARDIOLOGY
Impact of Vessel Size on Outcome After Implantation of Sirolimus-Eluting and Paclitaxel-Eluting StentsA Subgroup Analysis of the SIRTAX Trial
Mario Togni, MD*,
Stéphanie Eber, BA*,
Jeannette Widmer, BA*,
Michael Billinger, MD*,
Peter Wenaweser, MD*,
Stéphane Cook, MD*,
Rolf Vogel, MD, PhD*,
Christian Seiler, MD, FACC*,
Franz R. Eberli, MD ,
Willibald Maier, MD ,
Roberto Corti, MD ,
Marco Roffi, MD ,
Thomas F. Lüscher, MD ,
Ali Garachemani, MD*,
Otto M. Hess, MD, FACC*,
Simon Wandel, MS ,
Bernhard Meier, MD, FACC*,
Peter Jüni, MD and
Stephan Windecker, MD*,*
* Department of Cardiology, University Hospital Bern, Switzerland
Department of Social and Preventive Medicine, University Hospital Bern, Switzerland
Department of Cardiology, University Hospital Zurich, Zurich, Switzerland.
Manuscript received January 22, 2007;
revised manuscript received June 7, 2007,
accepted June 25, 2007.
* Reprint requests and correspondence: Dr. Stephan Windecker, Professor and Head of Invasive Cardiology, Department of Cardiology, University Hospital, 3010 Bern, Switzerland. (Email: stephan.windecker{at}insel.ch).
Objectives: We assessed the impact of vessel size on angiographic and long-term clinical outcome after percutaneous coronary intervention (PCI) with sirolimus-eluting stents (SES) and paclitaxel-eluting stents (PES) within a randomized trial (SIRTAX [Sirolimus-Eluting Stent Compared With Paclitaxel-Eluting Stent for Coronary Revascularization]).
Background: Percutaneous coronary intervention in small-vessel disease is associated with an increased risk of major adverse cardiac events (MACE).
Methods: A total of 1,012 patients were randomly assigned to treatment with SES (n = 503) or PES (n = 509). A stratified analysis of angiographic and clinical outcome was performed up to 2 years after PCI according to size of the treated vessel (reference vessel diameter 2.75 vs. >2.75 mm).
Results: Of 1,012 patients, 370 patients (37%) with 495 lesions underwent stent implantation in small vessels only, 504 patients (50%) with 613 lesions in large vessels only, and 138 patients (14%) with 301 lesions in both small and large vessels (mixed). In patients with small-vessel stents, SES reduced MACE by 55% (10.4% vs. 21.4%; p = 0.004), mainly driven by a 69% reduction of target lesion revascularization (TLR) (6.0% vs. 17.7%; p = 0.001) compared with PES at 2 years. In patients with large- and mixed-vessel stents, rates of MACE (large: 10.4% vs. 13.1%; p = 0.33; mixed: 16.7% vs. 18.0%; p = 0.83) and TLR (large: 6.9% vs. 8.6%; p = 0.47; mixed: 16.7% vs. 15.4%; p = 0.86) were similar for SES and PES. There were no significant differences with respect to death and myocardial infarction between the 3 groups.
Conclusions: Compared with PES, SES more effectively reduced MACE and TLR in small-vessel disease. Differences between SES and PES appear less pronounced in patients with large- and mixed-vessel disease. (The SIRTAX trial; http://clinicaltrials.gov/ct/show/NCT00297661?order=1; NCT00297661
[ClinicalTrials.gov]
).
|
Abbreviations and Acronyms
| | DES = drug-eluting stent(s) | | MACE = major adverse cardiac events | | PCI = percutaneous coronary intervention | | PES = paclitaxel-eluting stent(s) | | RVD = reference vessel diameter | | SES = sirolimus-eluting stent(s) | | TLR = target lesion revascularization |
|
Related Article
-
Inside This Issue of JACC
J. Am. Coll. Cardiol. 2007 50: A25-A26.
[Full Text]
[PDF]
This article has been cited by other articles:

|
 |

|
 |
 
C. Girasis, S. Garg, L. Raber, G. Sarno, M.-A. Morel, H. M. Garcia-Garcia, T. F. Luscher, P. W. Serruys, and S. Windecker
SYNTAX score and Clinical SYNTAX score as predictors of very long-term clinical outcomes in patients undergoing percutaneous coronary interventions: a substudy of SIRolimus-eluting stent compared with pacliTAXel-eluting stent for coronary revascularization (SIRTAX) trial
Eur. Heart J.,
December 2, 2011;
32(24):
3115 - 3127.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. Cortese, A. Micheli, A. Picchi, A. Coppolaro, L. Bandinelli, S. Severi, and U. Limbruno
Paclitaxel-coated balloon versus drug-eluting stent during PCI of small coronary vessels, a prospective randomised clinical trial. The PICCOLETO Study
Heart,
August 1, 2010;
96(16):
1291 - 1296.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Menozzi, E. Solinas, P. Ortolani, A. Repetto, F. Saia, G. Piovaccari, A. Manari, E. Magagnini, L. Vignali, E. Bonizzoni, et al.
Twenty-four months clinical outcomes of sirolimus-eluting stents for the treatment of small coronary arteries: the long-term SES-SMART clinical study
Eur. Heart J.,
September 1, 2009;
30(17):
2095 - 2101.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. J. Wykrzykowska, P. W. Serruys, Y. Onuma, T. de Vries, G.-A. van Es, P. Buszman, A. Linke, T. Ischinger, V. Klauss, R. Corti, et al.
Impact of Vessel Size on Angiographic and Clinical Outcomes of Revascularization With Biolimus-Eluting Stent With Biodegradable Polymer and Sirolimus-Eluting Stent With Durable Polymer: The LEADERS Trial Substudy
J. Am. Coll. Cardiol. Intv.,
September 1, 2009;
2(9):
861 - 870.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Peters, B. Behnisch, T. Heilmann, and C. Richter
First-in-man use of polymer-free valsartan-eluting stents in small coronary vessels: a comparison to polymer-free rapamycin (2%)-eluting stents
Journal of Renin-Angiotensin-Aldosterone System,
June 1, 2009;
10(2):
91 - 95.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
S. R. Dixon, C. L. Grines, and W. W. O'Neill
The Year in Interventional Cardiology
J. Am. Coll. Cardiol.,
June 17, 2008;
51(24):
2355 - 2369.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Billinger, J. Beutler, K. R. Taghetchian, A. Remondino, P. Wenaweser, S. Cook, M. Togni, C. Seiler, C. Stettler, F. R. Eberli, et al.
Two-year clinical outcome after implantation of sirolimus-eluting and paclitaxel-eluting stents in diabetic patients
Eur. Heart J.,
March 2, 2008;
29(6):
718 - 725.
[Abstract]
[Full Text]
[PDF]
|
 |
|
|